Abstract
As pregnant women are considered a high-risk group for severe influenza illness, current recommendations advise vaccination of all pregnant women with inactivated influenza vaccine. Nevertheless, rates of maternal influenza vaccination have historically been low, possibly reflecting ongoing concerns about vaccine safety. Until recently, the majority of evidence concerning safety of influenza vaccination during pregnancy was limited to post-marketing pharmacovigilance studies; however, in the past 5 years, one randomized clinical trial and a number of observational studies reflecting seasonal trivalent inactivated influenza vaccines and monovalent H1N1 influenza vaccines have been published. This review summarizes the evidence pertaining to fetal and neonatal outcomes following influenza vaccination during pregnancy for comparative analytic studies published between 2008 and August 2013. Since the majority of these studies are observational in nature, issues related to study quality are also addressed.
| Original language | English |
|---|---|
| Pages (from-to) | 1417-1430 |
| Number of pages | 14 |
| Journal | Expert Review of Vaccines |
| Volume | 12 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - Dec 2013 |
Bibliographical note
Funding Information:S McNeil has participated in clinical trials from influenza vaccine manufacturers (Sanofi, GSK, Novartis) and has previously received research funding from Sanofi and GSK. None of the other authors have any relevant affiliations or financial involvement with any organization or entity with a financial interest conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
ASJC Scopus Subject Areas
- Immunology
- Molecular Medicine
- Pharmacology
- Drug Discovery
PubMed: MeSH publication types
- Journal Article
- Research Support, Non-U.S. Gov't
- Review
